Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 16,500 ...

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D., ...

Citizens Jmp upgraded shares of Astria Therapeutics (NASDAQ:ATXS – Free Report) to a strong-buy rating in a report published on Friday,Zacks.com reports. Other equities analysts have also recently ...

Fintel reports that on January 31, 2025, JMP Securities initiated coverage of Astria Therapeutics (NasdaqGM:ATXS) with a Market Outperform recommendation. Analyst Price Forecast Suggests 244.82% ...

JMP Securities initiated coverage on Astria Therapeutics (NASDAQ: ATXS), assigning a Market Outperform rating and setting a ...

JMP Securities analyst Jonathan Wolleben initiated coverage of Astria Therapeutics (ATXS) with an Outperform rating and $26 price target ...

Jonathan Wolleben, an analyst from JMP Securities, has initiated a new Buy rating on Astria Therapeutics (ATXS).Invest with Confidence: Follow ...

Longer Term Trading Plans for ATXS. Buy ATXS near 7.19 target 9.02 stop loss @ 7.17 Details; The technical summary data tells us to buy ATXS near 7.19 with an upside target of 9.0 ...

HC Wainwright reiterated their buy rating on shares of Astria Therapeutics (NASDAQ:ATXS – Free Report) in a research report released on Thursday,Benzinga reports. HC Wainwright currently has a $ ...

Rokid made waves in global AR scene, showcasing a suite of groundbreaking products, including Rokid Glasses, Rokid AR Spatial, and advanced business solutions for smart tours, reaffirming its ...